Dexcom and Google Life Sciences will develop an affordable and efficient slap-on glucose tracker
Google enters the gates of medicine with a new initiative aimed at helping individuals who must deal with diabetes. The illness is widespread in the US, with more than 29.1 million people suffering and changing their lifestyle because of it. In most cases, the condition requires long term medication and important dietary changes, based on the patient’s daily glucose levels. Dexcom, an important company in the sensor-making business will work together with the Life Sciences division of Google to develop a glucose tracker.
Google wants to give a helping hand to those in need and embarked on a mission aimed at upgrading a miniature glucose tracker, namely a sensor that picks up glucose levels under the patient’s skin. The sensor is equipped with a special transmitter able to send readings every five minutes to a monitor. With the special device, patients can use their registered glucose patterns in order to make the best decisions about their daily nutrition routines. Google’s mission is to advance the new system in such a way as to save important costs and offer it to end consumers at a most affordable price.
The new and disposable version of the slap-on sensor will eventually replace the bulk of blood-monitoring devices. It was first imagined and created by Dexcom, one of the world’s greatest sensor makers through advanced technology.
Dexcom’s present CGM system is designed to work for both Type 1 and Type 2 diabetes. The cost of the device is pretty high for the time being but the new partnership with Life Sciences will make it more consumer-friendly and will probably advance some features in order to make it more efficient and highly accurate for the entire pool of individuals who need to constantly monitor their health levels.
Google will be offered the chance to improve its database with precious information regarding patients and diabetes. The company will soon become a steady partner in the healthcare business, providing both financial resources and personal information which will come as a helping hand to experts that need to deepen their insights on diabetes for starters, and maybe on some other widespread diseases that cause victims among communities.
A first general goal of the new partnership is to provide every patient with these kinds of devices, allowing them to gain more control of real-time glucose levels and appropriate information about important actions that need to be taken, based on the constantly updated information.
Products will be exclusively retailed by Dexcom, which signed to pay Life Sciences $35 million in stock and an additional $65 million in stock or cash, as the partnership reaches a peak in development.
Image Source: iran-daily.com
